A5047323010- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- Influenza Virus Research Studies
- Viral Infections and Immunology Research
- Peripheral Neuropathies and Disorders
- COVID-19 Clinical Research Studies
- Animal Virus Infections Studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Blood transfusion and management
- Bacterial Infections and Vaccines
- COVID-19 and healthcare impacts
- Endometriosis Research and Treatment
- Sarcoma Diagnosis and Treatment
- Pericarditis and Cardiac Tamponade
- Reproductive Health and Contraception
- Statistical Methods and Bayesian Inference
- Endometrial and Cervical Cancer Treatments
- COVID-19 epidemiological studies
- Long-Term Effects of COVID-19
- COVID-19 Impact on Reproduction
- Gold and Silver Nanoparticles Synthesis and Applications
- Pharmacovigilance and Adverse Drug Reactions
- Advanced biosensing and bioanalysis techniques
- Bone Tumor Diagnosis and Treatments
- Gastrointestinal disorders and treatments
Acumen (United States)
2019-2025
Kunming Children's Hospital
2025
Yichang Central People's Hospital
2025
China Three Gorges University
2025
Guangxi Normal University
2013
Importance Active monitoring of health outcomes after COVID-19 vaccination provides early detection rare that may not be identified in prelicensure trials. Objective To conduct near-real-time the US pediatric population. Design, Setting, and Participants This cohort study evaluated 21 prespecified exposure before 2023 to BNT162b2, mRNA-1273, or NVX-CoV2373 ancestral monovalent vaccines children aged 6 months 17 years by applying a framework using care data from 3 commercial claims databases...
Abstract Background The current study was performed to evaluate risk factors for severe coronavirus disease 2019 (COVID-19) outcomes among Medicare beneficiaries during the pandemic’s early phase. Methods In a retrospective cohort covering fee-for-service beneficiaries, we separated out elderly residents in nursing homes (NHs) and those with end-stage renal (ESRD) from primary population of individuals age ≥65 years. Outcomes included COVID-19 hospital encounters COVID-19-associated deaths....
Importance Active monitoring of health outcomes after COVID-19 vaccination offers early detection rare that may not be identified in prelicensure trials. Objective To conduct near–real-time following BNT162b2 the US pediatric population aged 5 to 17 years. Design, Setting, and Participants This population-based study was conducted under a public surveillance mandate from Food Drug Administration. years were included if they received through mid 2022 had continuous enrollment medical...
Background Influenza vaccination is widely recommended for individuals aged 6 months and older in the United States (U.S.). While safety of annual influenza vaccines well established, FDA conducts routine monitoring evaluation safety. This study assessed 2023-2024 among elderly U.S. Medicare beneficiaries. Methods A self-controlled case series (SCCS) analysis compared incidence rate ratios (IRR) anaphylaxis, encephalitis/encephalomyelitis/acute disseminated encephalomyelitis, Guillain-Barre...
Background COVID-19 vaccines are well-established as safe. However, continued surveillance of is important to ensure the safety newly formulated vaccines. This study evaluated association between vaccination with 2023-2024 formula and multiple health outcomes among Medicare beneficiaries aged 65 years older in United States. Methods The used plan data from Fee-for-Service (FFS) claims database extended September 2023 April 2024. We monitored uptake (Pfizer-BioNTech, Moderna, Novavax), where...
To summarize and analyze the characteristics of delayed hemolytic transfusion reaction in children, order to provide a scientific basis for clinical prevention, ensure safety children's blood transfusion. The basic situation, symptoms signs, diagnosis time disappearance alloantibody children were retrospectively analyzed. serological test, routine biochemical detection urine analysis results compared pre- post-transfusion. Among 15 164 with repeated transfusion, 23 cases occurred reactions,...
The U.S. Food and Drug Administration (FDA) Biologics Effectiveness Safety (BEST) Initiative conducts active surveillance of adverse events special interest (AESI) after COVID-19 vaccination. Historical incidence rates (IRs) AESI are comparators to evaluate safety.We estimated IRs 17 in six administrative claims databases from January 1, 2019, December 11, 2020: Medicare for adults ≥ 65 years commercial (Blue Health Intelligence®, CVS Health, HealthCore Integrated Research Database, IBM®...
Examining medical products' benefits and risks in different population subsets is often necessary for informing public health decisions. In observational cohort studies, safety analyses by pre-specified subgroup can be powered, are informative about subsets' if the study designs or adequately control confounding. However, few guidelines exist on how to simultaneously confounding conduct analyses. this simulation study, we evaluated performance, terms of bias, efficiency coverage, six...
Abstract Active monitoring of health outcomes after COVID-19 vaccination provides early detection rare post-licensure. Objective To evaluate following bivalent Pfizer-BioNTech (BNT162b2) and Moderna (mRNA-1273.222) among individuals 6 months older in the United States. Design Monthly from August 2022 to July 2023 four administrative claims databases. Descriptive analyses monitored vaccine uptake, outcome counts coadministration influenza vaccines. Sequential tested for elevated risk each a...
The Vaccine Safety Datalink (VSD) identified a statistical signal for an increased risk of Guillain-Barré syndrome (GBS) in days 1-42 after 2018-2019 high-dose influenza vaccine (IIV3-HD) administration. We evaluated the using Medicare.We conducted early- and end-of-season claims-based self-controlled interval analyses among Medicare beneficiaries ages ≥65 years, 8-21 postvaccination as windows 43-84 control window. VSD chart-confirmed analyses.Among 7 453 690 IIV3-HD vaccinations, we did...
Vaccine use during pregnancy affects maternal and infant health. Many women do not receive vaccines recommended pregnancy; conversely, inadvertent exposure to contraindicated or may occur. We assessed two among privately Medicaid-insured in the United States.This study includes a retrospective cohort of pregnancies aged 12-55 years resulting live birth, spontaneous abortion, stillbirth identified IBM® MarketScan® Commercial, Blue Health Intelligence® (BHI®) IBM MarketScan Multi-State...
ABSTRACT Objective To evaluate febrile seizure risk following monovalent COVID-19 mRNA vaccination among children aged 2-5 years. Methods The primary analysis evaluated who had a outcome in the 0-1 days vaccination. A self-controlled case series was performed three commercial insurance databases to compare of interval (0-1 days) control (8-63 days). exposure interest receipt dose 1 and/or 2 vaccinations. day interval). conditional Poisson regression model used rates and intervals estimate...
Abstract Background While safety of influenza vaccines is well-established, some studies have suggested potential associations between and certain adverse events (AEs). This study examined the 2022–2023 among U.S. adults ≥ 65 years. Methods A self-controlled case series compared incidence rates anaphylaxis, encephalitis/encephalomyelitis, Guillain Barré-Syndrome (GBS), transverse myelitis following seasonal vaccinations (i.e., any, high-dose or adjuvanted) in risk control intervals Medicare...
Abstract Importance Active monitoring of health outcomes after COVID-19 vaccination provides early detection rare that may not be identified in prelicensure trials. Objective To conduct near real-time following the United States (US) pediatric population aged 6 months to 17 years. Design We evaluated 21 pre-specified outcomes; 15 were sequentially tested through surveillance, and monitored descriptively within a cohort vaccinated children. for increased rate each outcome compared historical...
Abstract Background The U.S. FDA authorized the monovalent third primary series or booster doses of COVID-19 mRNA vaccines in August 2021 for persons 18 years and older. Monitoring outcomes following updated authorizations is critical to evaluate vaccine safety can provide early detection rare adverse events (AEs) not identified pre-licensure trials. Methods We evaluated risk 17 AEs from through 2022 among adults aged 18-64 three commercial databases (Optum, Carelon Research, CVS Health)...